Oncolytic virotherapy is an emerging treatment modality that uses replication-competent
viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-…

To achieve therapeutic success, transfer vehicles for gene therapy must be capable of
transducing target cells while avoiding impact on non-target cells. Despite the high transduction …

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex)
as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given …

… ● Pomalidomide dosed from 1 to 5 mg/mL has been shown to be well tolerated in Phase
I trials in patients with relapsed MM (Br J Haematol 2008;141:41). … J Clin Oncol 2009;27(30):5008-14 …

Live attenuated Edmonston B strain of measles virus (MV-Edm) is a potent and specific oncolytic
agent, but the mechanism underlying its tumor selectivity is unknown. The virus causes …

Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide,
especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. …

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction
of novel therapies and the increased use of high-dose therapy have translated into better …

… Author links open overlay panel Stephen J. Russell MD, PhD a b , Mark J. Federspiel PhD
a , Kah-Whye Peng PhD a , Caili Tong MS a , David Dingli MD, PhD a b , William G. Morice MD…

Live attenuated measles viruses of the Edmonston lineage (MV-Edm) have potent anti-tumor
activity 1 , 2 , 3 , 4 but are not entirely tumor-specific owing to widespread distribution of …

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the
introduction of new drugs, but it is not clear whether the improvements have been sustained. We …